Relative risk (hazard rates) of relapse according to the univariate analysis (Cox regression) stratified by centre
| Variable | HBeAg relapse | HBV DNA relapse | ||
|---|---|---|---|---|
| Variable | Relative risk (95% CI) | p Value (log likelihood) | Relative risk (95% CI) | p Value (log likelihood) |
| IFN, interferon; LAM, lamivudine; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase; ULN, upper limit of normal; RCT, randomised controlled trial | ||||
| Therapy | 0.0008 | 0.0005 | ||
| IFN | 1 | 1 | ||
| LAM | 7.4 (2.5–22.4) | 0.0003 | 7.1 (2.4–20.1) | 0.0002 |
| Combination | 1.3 (0.8–4.5) | 0.68 | 1.1 (0.3–3.8) | 0.87 |
| Age (y) | 1.00 (0.98–1.02) | 0.87 | 1.00 (0.98–1.03) | 0.70 |
| Sex | ||||
| Male | 1 | |||
| Female | 0.4 (0.2–0.9) | 0.02 | 0.5 (0.2–1.1) | 0.05 |
| Race | ||||
| Caucasian | 1 | 1 | ||
| Asian | 0.8 (0.3–2.3) | 0.75 | 1.0 (0.4–2.6) | 0.97 |
| Previous therapy | 0.24 | 0.05 | ||
| None | 1 | 1 | ||
| IFN | 1.3 (0.6–2.6) | 0.49 | 1.4 (0.7–2.7) | 0.37 |
| LAM | 3.9 (0.8–19.3) | 0.11 | 6.6 (1.4–31.3) | 0.02 |
| Study type | ||||
| RCT | 1 | 1 | ||
| Cohort | 1.3 (0.3–5.6) | 0.75 | 1.85 (0.5–6.8) | 0.38 |
| HBV DNA (log) | 1.51 (1.04–2.21) | 0.03 | 1.50 (1.03–2.19) | 0.03 |
| HBV DNA | ||||
| HBV DNA <108 | 1 | 1 | ||
| HBV DNA >108 | 2.2 (1.2–4.2) | 0.01 | 2.1 (1.1–3.8) | 0.02 |
| ALT (×ULN) | 0.04 | 0.07 | ||
| ≤2 | 1 | 1 | ||
| 2–5 | 0.4 (0.2–0.9) | 0.03 | 0.5 (0.2–1.0) | 0.04 |
| ≥5 | 0.4 (0.1–0.9) | 0.02 | 0.4 (0.2–1.0) | 0.04 |
| Duration of lamivudine therapy | 0.28 | 0.22 | ||
| 24–48 weeks | 1 | 1 | ||
| 48–72 weeks | 0.4 (0.2–1.2) | 0.11 | 0.4 (0.2–1.1) | 0.09 |
| >72 weeks | 0.5 (0.1–2.8) | 0.45 | 0.7 (0.2–2.8) | 0.57 |